CDK7 inhibitor samuraciclib shows promise against resistant breast cancer in randomized trial

For the hundreds of thousands of women living with metastatic breast cancer worldwide, the arrival of CDK4/6 inhibitors over the past decade transformed a disease once managed primarily with chemotherapy into a chronic condition that could often be controlled for years with targeted oral therapy. Yet that transformation carries an expiration date. When tumors eventually stop responding to these drugs, patients with hormone receptor-positive, HER2-negative disease face a therapeutic landscape with few clearly superior options. Now, a randomized controlled trial published in Nature Communications offers a glimpse of what may come next: an entirely new class of drug that attacks cancer through a mechanism fundamentally different from anything currently in the clinic.

The trial, led by Sonia Pernas of the Institut Català d’Oncologia and Bellvitge Biomedical Research Institute in Barcelona, tested samuraciclib, an oral and highly selective inhibitor of cyclin-dependent kinase 7, in combination with fulvestrant, a standard endocrine therapy that degrades the estrogen receptor. The study enrolled 59 women with advanced HR-positive, HER2-negative breast cancer whose disease had already progressed after treatment with a CDK4/6 inhibitor, the current mainstay of first-line therapy. Participants were randomly assigned to one of three arms: samuraciclib at 360 milligrams plus fulvestrant, samuraciclib at 240 milligrams plus fulvestrant, or fulvestrant alone. Randomization was stratified by TP53 mutation status and the presence of liver metastases, two factors known to influence prognosis in this disease.

The biology behind samuraciclib is what makes this trial scientifically significant. While CDK4/6 inhibitors block the cell cycle machinery that drives cell division, CDK7 occupies a more upstream and more fundamental position in the cancer cell’s architecture. It serves as a component of the transcription factor II H complex, which phosphorylates the RNA polymerase II enzyme and enables the transcription of genes into messenger RNA. By inhibiting CDK7, samuraciclib disrupts the expression of transcriptional programs that sustain tumor growth, including those governing estrogen receptor signaling, MYC-driven proliferation, and the super-enhancer networks that many cancers depend upon for survival. This mechanism of action means that even tumors that have evolved resistance to cell cycle blockade may remain vulnerable to transcriptional disruption, because the drug targets the very machinery that produces the proteins driving malignancy.

The primary endpoint of the trial was the clinical benefit rate, a composite measure capturing patients whose disease either shrank measurably or remained stable for a clinically meaningful duration. The results showed a clear signal. In the 360-milligram samuraciclib arm, the clinical benefit rate reached 60.0 percent. In the 240-milligram arm, it was 63.2 percent. In contrast, patients receiving fulvestrant alone achieved a clinical benefit rate of just 40.0 percent. Both samuraciclib doses, therefore, outperformed the standard endocrine therapy by a margin of roughly 20 to 23 percentage points, a difference that is notable in a population whose disease has already evaded multiple lines of targeted treatment.

Beyond the overall comparison, the investigators conducted prespecified secondary analyses in molecularly and clinically defined subgroups, and the results there were even more striking. Among patients whose tumors carried no detectable TP53 mutations, meaning they were classified as TP53 wild-type, the benefit of adding samuraciclib appeared enhanced. The same pattern held for participants who had no liver metastases at baseline, a group generally associated with less aggressive disease biology, and for those whose prior CDK4/6 inhibitor treatment had lasted at least twelve months, suggesting their tumors retained some degree of endocrine sensitivity. These subgroup findings point toward a biomarker-driven strategy in which TP53 status could serve as a predictive marker for identifying the patients most likely to benefit from CDK7 inhibition.

The significance of the TP53 wild-type subgroup deserves particular attention. TP53, often called the guardian of the genome, is the most frequently mutated gene in human cancer, and its loss is associated with genomic instability, aggressive behavior, and resistance to many therapies. In hormone receptor-positive breast cancer, TP53 mutation status has emerged as a potential determinant of how tumors respond to endocrine and targeted interventions. The observation that samuraciclib’s benefit was concentrated in patients with intact TP53 function suggests that the transcriptional dependency being targeted by CDK7 inhibition may be particularly critical in tumors that have not yet lost this key tumor suppressor pathway. This finding provides a clear rationale for the next generation of clinical trials to enrich enrollment with TP53 wild-type patients.

Safety data from the trial indicated that the adverse events associated with samuraciclib were predominantly gastrointestinal in nature. Nausea, vomiting, and diarrhea were the most commonly reported toxicities, consistent with the known profile of transcriptional inhibitors that can affect rapidly renewing epithelial tissues in the gut. Importantly, the investigators noted that these effects were manageable with prophylactic measures, meaning that supportive care strategies such as antiemetic medications and antidiarrheal agents could control the symptoms effectively. No new or unexpected safety signals emerged that would preclude further development of the combination, and the tolerability profile appeared acceptable for a population of patients with advanced disease who have often already endured multiple prior therapies.

The trial’s design as a three-arm randomized study rather than a single-arm expansion is a methodological strength that lends credibility to its findings. By including a fulvestrant monotherapy control arm, the investigators were able to isolate the contribution of samuraciclib from the background activity of endocrine therapy, which remains partially effective even after CDK4/6 inhibitor resistance has developed. The stratification by TP53 mutation status and liver metastases at randomization further ensured that known prognostic factors were balanced across treatment groups, reducing the likelihood that the observed differences in clinical benefit were artifacts of unequal patient characteristics. With 59 patients randomized across three arms, however, the study remains a relatively small trial, and the confidence intervals around the reported benefit rates are correspondingly wide.

These results arrive at a moment when the field of HR-positive metastatic breast cancer is actively searching for its next therapeutic paradigm. Several competing strategies are under investigation, including novel CDK2 and CDK4/6 inhibitors, AKT pathway inhibitors, and antibody-drug conjugates, each targeting a different vulnerability of resistant tumors. Samuraciclib’s approach is distinctive in that it does not attempt to re-inhibit the cell cycle or to deliver cytotoxic payloads, but instead to shut down the transcriptional output of the cancer cell at its source. The drug was developed by Carrick Therapeutics, which designed and funded the study, and the company’s scientists Glen Clack, Ash Bahl, and Stuart McIntosh are co-authors alongside clinical investigators from centers across Spain, Turkey, Mexico, the United States, and the United Kingdom.

The authors conclude that these findings support CDK7 inhibition with samuraciclib plus fulvestrant as a potential second-line strategy in HR-positive, HER2-negative breast cancer, and they explicitly call for a biomarker-enriched clinical evaluation focusing on TP53 wild-type tumors. Whether this approach will ultimately translate into improved survival outcomes will require larger, phase 3 trials with overall survival and quality-of-life endpoints. But for a patient population that has long awaited a genuinely new mechanism of action after CDK4/6 inhibitor failure, the demonstration that a transcriptional inhibitor can meaningfully extend clinical benefit in a randomized setting represents a conceptual advance that may reshape the therapeutic sequence for this common and challenging disease.

Subject of Research: A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer

Article Title: A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer

Article References: Pernas, S., Karacin, C., Gonzalez-Nuñez, C., Aksoy, S., Bellet Ezquerra, M., Karadurmus, N., Yazici, O., Abu-Khalaf, M., Bermejo de lasHeras, B., Gonzalez Cordero, M., Gumus, M., Hinojo, C., Lozano Mejorada, R., de la Mora Jimenez, E., Zuloaga Fernandez del Valle, C., Arslan, C., Kurian, S., Martínez García, M., Motola-Kuba, D., … Coombes, R. C. (2026). A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer. Nature Communications. https://doi.org/10.1038/s41467-026-78309-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78309-y

Keywords: breast cancer, CDK7 inhibitor, samuraciclib, fulvestrant, hormone receptor positive, targeted therapy, clinical trial, oncology, drug resistance, transcriptional inhibition, randomized, controlled